These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 37485727)

  • 41. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
    Rolinski M; Fox C; Maidment I; McShane R
    Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinesterase inhibitors for the treatment of delirium in non-ICU settings.
    Yu A; Wu S; Zhang Z; Dening T; Zhao S; Pinner G; Xia J; Yang D
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012494. PubMed ID: 29952000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rivastigmine for vascular cognitive impairment.
    Birks J; McGuinness B; Craig D
    Cochrane Database Syst Rev; 2013 May; (5):CD004744. PubMed ID: 23728651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cholinesterase inhibitors for Parkinson's disease dementia.
    Maidment I; Fox C; Boustani M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rivastigmine for Alzheimer's disease.
    Birks JS; Chong LY; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Sep; 9(9):CD001191. PubMed ID: 26393402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
    Wolfson C; Oremus M; Shukla V; Momoli F; Demers L; Perrault A; Moride Y
    Clin Ther; 2002 Jun; 24(6):862-86; discussion 837. PubMed ID: 12117079
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
    Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
    Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
    Wesnes K
    Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rivastigmine for vascular cognitive impairment.
    Craig D; Birks J
    Cochrane Database Syst Rev; 2005 Apr; (2):CD004744. PubMed ID: 15846730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
    Tricco AC; Soobiah C; Berliner S; Ho JM; Ng CH; Ashoor HM; Chen MH; Hemmelgarn B; Straus SE
    CMAJ; 2013 Nov; 185(16):1393-401. PubMed ID: 24043661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J ; Iakovidou V; Tsolaki M
    Cochrane Database Syst Rev; 2000; (4):CD001191. PubMed ID: 11034705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 3.